Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2019-06-18
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies cabozantinib-s-malate in treating patients with
hormone-resistant metastatic prostate cancer. Cabozantinib-s-malate may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth